[New therapeutic prospects in Alzheimer disease].
The approval for marketing of tacrine (Cognex), an acetylcholinesterase inhibitor, allowed physicians and the general people to attract attention to a degenerative disease, which prevalence dramatically increases every year. This drug is hopeful. Meanwhile, we must keep in mind that it has only a symptomatic effect. Its hepatotoxicity requires regular biological tests. Many medications are actually in earlier stages of development along with various etiological approaches.
Rouhart
F
F
Service de neurologie, CHU Augustin-Morvan, Brest, France.
D000544:Alzheimer Disease / Q000188:drug therapy / Q000628:therapy*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D005544:Forecasting; D015316:Genetic Therapy; D006801:Humans; D013619:Tacrine / Q000627:therapeutic use*
D002800:Cholinesterase Inhibitors; D013619:Tacrine
Nouvelles perspectives thérapeutiques dans la maladie d'Alzheimer.